Company profile
NOVAVAX INC
NASDAQ:NVAXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MATRIX-M1 ADJUVANT | phase3 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02296463 | phase1 | completed | 2014-11-01 | 2015-09-01 | Novavax | A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age |
| NCT06409663 | phase3 | completed | 2024-10-14 | 2024-10-15 | Novavax | A Strain Change Study for SARS-CoV-2 rS Vaccines |
| NCT04533399 | phase2 | completed | 2020-08-17 | 2021-12-07 | Novavax | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults |
| NCT04583995 | phase3 | completed | 2020-09-28 | 2022-03-29 | Novavax | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom |
| NCT02624947 | phase3 | completed | 2015-12-01 | 2018-12-28 | Novavax | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization |
FDA applications (0)
No records yet.